Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.

Clinical therapeutics - 1 Feb 2015

Childs-Kean Lindsey M, Hand Elizabeth O

Abstract excerpt

PURPOSE: Chronic hepatitis C infection affects a large proportion of the world's population and can lead to significant morbidity and mortality. The standard of care for treatment of hepatitis C infection has been peginterferon and ribavirin, with or without a first-generation protease inhibitor. In late 2013 and early 2014, sofosbuvir and simeprevir obtained regulatory approval, offering the first possibility...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase II as Topic
Share to Clinical Trials, Phase III as Topic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Headache

Share to Nausea

Share to Polyethylene Glycols

Share to Protease Inhibitors

Share to Simeprevir

Share to Sofosbuvir

Source

Identifiers

PMID: 25601269
DOI: 10.1016/j.clinthera.2014.12.012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.PMID 25601269Read ↗

Simeprevir and sofosbuvir for treatment of hepatitis C infection.Semantic proximity Read ↗

Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence.Semantic proximity Read ↗

Simeprevir for the treatment of chronic hepatitis C.Semantic proximity Read ↗

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.Semantic proximity Read ↗

Simeprevir for the treatment of chronic hepatitis C genotype 1 infection.Semantic proximity Read ↗

Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO).Semantic proximity Read ↗

Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial.Semantic proximity Read ↗

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.Semantic proximity Read ↗

Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience.Semantic proximity Read ↗

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.Semantic proximity Read ↗

Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.Semantic proximity Read ↗

Sofosbuvir for previously untreated chronic hepatitis C infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.